PSTV
Plus Therapeutics, Inc. [PSTV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PSTV Stock Summary
In the News
PSTV Financial details
Company Rating
-
Market Cap
7.95M
Income
-13.32M
Revenue
4.91M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
-0.41
Forward P/E
-
PEG
0.07
P/S
4.22
P/B
2.39
P/C
-
P/FCF
-0.66
Quick Ratio
1.05
Current Ratio
1.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.5
EPS next Y
-
EPS next Q
-
EPS this Y
-64.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-50.18%
Revenue last 5Y
-6.83%
Revenue Q/Q
5.89%
EPS Q/Q
-16%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-115%
ROE
-424%
ROC
-5.49%
Gross Margin
100%
Oper. Margin
-723%
Profit Margin
-734%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.97-5.1
52W High
-
52W Low
-
RSI
49
Rel Volume
78.28
Avg Volume
29.79K
Volume
2.33M
Perf Week
-29.99%
Perf Month
-16.58%
Perf Quarter
-26.39%
Perf Half Y
-45.89%
-
-
-
-
Beta
0.558
-
-
Volatility
0.22%, 0.36%
Prev Close
5.37%
Price
1.0011
Change
-10.62%
Company Profile
- Volume Average 29.79K
- Market Capitalization 7.95M
- Employee 20
- CEO Dr. Marc H. Hedrick M.B.A., M.D.
- Headquarters Austin,TX,US
- IPO Date 2001-07-11
-
Website
https://www.plustherapeutics.com 
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
